P.K. Shenoy, MD, DLO, FRCS, FACS1, W. Wang, MD2
1ENT Service Chief, Campbellton Regional Hospital, New Brunswick, Campbellton, Canada. 2Pathology Service Chief, Campbellton Regional Hospital, New Brunswick, Campbellton, Canada.
Abstract
Lymphoma accounts for 3 to 5% of malignant tumours, non-Hodgkin's lymphoma (NHL) accounts for 60% of all lymphoma. NHL of the sinonasal tract is an uncommon neoplasm that can be morphologically difficult to distinguish from non-neoplastic destructive lesions or malignant neoplasm. Only Immuno histochemistry could give a definite diagnosis. These represent 1.5 to 15% of NHL in the United States,1 2.6 to 6.7% of all lymphoma in Asia.2 B cell phenotype are most frequently found in the Western Hemisphere while T cell lymphomas are found in Asian countries. B-cell lymphoma of sinonasal tract occur in 6th to 8th decade of life and have a better prognosis.3 Review of the literature shows that early diagnosis and prompt treatment with local radiation (XRT) or combined modality treatment (CMT) have shown good prognosis.4
Keywords: non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), disease free survival (DFS), overall survival (OS), epistaxis, rapid rhino® (Arthrocare ENT products).
